Clinical Trials
21 trialsNCT00183937 2026-05-15
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
University of Southern California
Phase 2 Terminated
NCT00479128 2026-04-16
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06029998 2025-11-28
BORXPTEN
University of Utah
Phase 2 Recruiting
NCT01827137 2024-09-19
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Sellas Life Sciences Group
Phase 1/2 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT00276614 2020-09-01
Bortezomib in Treating Patients With Metastatic Kidney Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00059631 2018-11-15
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00103376 2018-11-05
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
Medical University of South Carolina
Phase 2 Terminated
NCT00622674 2017-12-02
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00620295 2017-11-29
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT01132911 2017-07-02
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00184015 2017-04-11
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
University of Southern California
Phase 1/2 Unknown
NCT01100242 2015-09-17
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00066352 2015-07-23
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
University Health Network, Toronto
Phase 2 Completed
NCT00425503 2014-04-21
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Baylor College of Medicine
Phase 2 Completed
NCT00025376 2013-09-05
PS-341 in Treating Patients With Metastatic Kidney Cancer
University of Chicago
Phase 2 Completed
NCT00072150 2013-06-05
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00667641 2011-05-10
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT00193232 2010-07-28
Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00017329 2009-12-15
PS-341 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00064610 2008-02-11
Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer
Millennium Pharmaceuticals, Inc.
Phase 1/2 Completed